---
figid: PMC9221178__cancers-14-02923-g004
figtitle: Microbial-Derived Toll-like Receptor Agonism in Cancer Treatment and Progression
organisms:
- Streptococcus pyogenes
- Fusobacterium nucleatum
- Serratia marcescens
- Mycobacterium intracellulare subsp. intracellulare
- Clostridium novyi NT
- Clostridium novyi
- Adenoviridae
- unidentified influenza virus
- Vaccinia virus
- DNA viruses
- Papaya mosaic virus
- Mus musculus
- Rattus norvegicus
- Drosophila melanogaster
- Toxoplasma gondii
- Homo sapiens
- Canis lupus familiaris
- Vigna unguiculata
organisms_ner:
- Homo sapiens
- Mus musculus
- Rattus norvegicus
- Canis lupus familiaris
- Drosophila melanogaster
- Danio rerio
pmcid: PMC9221178
filename: cancers-14-02923-g004.jpg
figlink: /pmc/articles/PMC9221178/figure/cancers-14-02923-f004/
number: F4
caption: TLR-MAPK/ERK signaling in the progression or regression of cancer. MAPK/ERK
  pathway activation can occur through MyD88-dependent or MyD88-independent TRIF signaling.
  The MyD88-dependent and -independent signaling converges in the activation of the
  TAK1 complex. Following the activation of the TAK1 complex, MEKK1/2, MKK4/7, and
  MKK3/6 are activated. MEKK1/2, MKK4/7, and MKK3/6 activation leads to the activation
  of ERK1/2, JNK, and p38 MAPK, respectively. Signaling from ERK1/2, JNK, and p38
  MAPK can promote tumor growth or inhibition, APC modulation, angiogenesis, and metastasis.
  Created with Biorender.com.
papertitle: Microbial-Derived Toll-like Receptor Agonism in Cancer Treatment and Progression.
reftext: Eileena F. Giurini, et al. Cancers (Basel). 2022 Jun;14(12):2923.
year: '2022'
doi: 10.3390/cancers14122923
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI
keywords: innate receptors | toll like receptors | cancer | immunotherapy | microbial
  based therapy
automl_pathway: 0.8882389
figid_alias: PMC9221178__F4
figtype: Figure
redirect_from: /figures/PMC9221178__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9221178__cancers-14-02923-g004.html
  '@type': Dataset
  description: TLR-MAPK/ERK signaling in the progression or regression of cancer.
    MAPK/ERK pathway activation can occur through MyD88-dependent or MyD88-independent
    TRIF signaling. The MyD88-dependent and -independent signaling converges in the
    activation of the TAK1 complex. Following the activation of the TAK1 complex,
    MEKK1/2, MKK4/7, and MKK3/6 are activated. MEKK1/2, MKK4/7, and MKK3/6 activation
    leads to the activation of ERK1/2, JNK, and p38 MAPK, respectively. Signaling
    from ERK1/2, JNK, and p38 MAPK can promote tumor growth or inhibition, APC modulation,
    angiogenesis, and metastasis. Created with Biorender.com.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TLR4
  - TIRAP
  - MYD88
  - IRAK1
  - IRAK4
  - TRAF6
  - MAP3K1
  - MAP3K2
  - MAPK3
  - MAP3K7
  - NR2C2
  - TAB2
  - TAB1
  - MAP2K4
  - MAPK8
  - MAPK9
  - MAPK10
  - UQCRFS1
  - RIPK1
  - RALBP1
  - KRR1
  - MAP2K3
  - MAP2K6
  - MAPK1
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - CRK
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - APC
  - PROC
  - HLA-C
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - CXCL8
  - TRIM69
  - TICAM1
  - TLR3
  - Tlr4
  - Tirap
  - Myd88
  - Irak1
  - Irak4
  - Traf6
  - Map2k1
  - Map3k1
  - Map3k2
  - Mapk3
  - Nr2c2
  - Map3k7
  - Tab2
  - Tab1
  - Map2k4
  - Mapk8
  - Ralbp1
  - Ripk1
  - Map2k3
  - Map2k6
  - Mapk14
  - Crk
  - Grap2
  - Syp
  - Ahsa1
  - Apc
  - Vegfa
  - Cxcl15
  - Rnf138
  - Trim69
  - Ticam1
  - Ticam2
  - Tlr3
  - Toll-4
  - Mekk1
  - rl
  - Tak1
  - Mkk4
  - bsk
  - lic
  - MKP-4
  - p38b
  - p38a
  - p38c
  - Nurf-38
  - Ebp
  - Hrb87F
  - Apc2
  - Axn
  - Fs(3)Apc
  - Mhc
  - zip
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - tirap
  - myd88
  - irak1
  - irak4
  - traf6
  - mapk3
  - tab2
  - tab1
  - map2k4a
  - mapk8b
  - ripk1l
  - map2k6
  - mapk14a
  - apc
  - vegfaa
  - cxcl8a
  - ticam1
  - tlr3
---
